Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Deffered Revenue of $2.2 million for Q4 2024, down 72.84% year-over-year from $7.9 million in Q1 2024, and down 72.84% quarter-over-quarter from $7.9 million in Q4 2023.
Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Deffered Revenue for 2 consecutive years, with $2.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Deffered Revenue fell 72.84% year-over-year to $2.2 million; the TTM figure through Dec 2024 stood at $2.2 million (down 72.84% YoY), while the FY2024 annual figure was $2.0 million, down 75.53% from the prior year.
- Non-Current Deffered Revenue declined to $2.2 million in Q4 2024 per TLX's latest filing, from $7.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $7.9 million in Q4 2023 and bottomed at $2.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 7.92 Mn |